Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.5% Higher – Still a Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s share price was up 0.5% during trading on Thursday . The company traded as high as $6.58 and last traded at $6.45. Approximately 3,646,349 shares changed hands during mid-day trading, a decline of 76% from the average daily volume of 14,902,363 shares. The stock had previously closed at $6.42.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on RXRX. KeyCorp decreased their target price on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Needham & Company LLC restated a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, Recursion Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $8.75.

Recursion Pharmaceuticals Trading Up 1.1 %

The stock’s 50 day moving average is $6.92 and its 200-day moving average is $6.96. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The company has a market capitalization of $2.54 billion, a P/E ratio of -4.23 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The firm had revenue of $26.08 million during the quarter, compared to analysts’ expectations of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company’s revenue for the quarter was up 147.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.43) EPS. As a group, equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.56 earnings per share for the current year.

Insider Activity at Recursion Pharmaceuticals

In related news, COO Tina Marriott sold 6,000 shares of the company’s stock in a transaction that occurred on Thursday, October 24th. The stock was sold at an average price of $6.31, for a total value of $37,860.00. Following the sale, the chief operating officer now owns 521,138 shares in the company, valued at $3,288,380.78. This represents a 1.14 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total value of $114,900.00. Following the transaction, the chief financial officer now owns 1,499,631 shares of the company’s stock, valued at $11,487,173.46. The trade was a 0.99 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 43,894 shares of company stock valued at $317,139 in the last three months. Company insiders own 15.75% of the company’s stock.

Institutional Trading of Recursion Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC bought a new stake in shares of Recursion Pharmaceuticals during the third quarter valued at approximately $25,000. Decker Retirement Planning Inc. purchased a new position in shares of Recursion Pharmaceuticals in the fourth quarter worth $26,000. GAMMA Investing LLC lifted its holdings in shares of Recursion Pharmaceuticals by 1,979.2% during the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock valued at $35,000 after purchasing an additional 4,948 shares in the last quarter. Farther Finance Advisors LLC boosted its position in shares of Recursion Pharmaceuticals by 176.9% during the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after buying an additional 4,091 shares during the last quarter. Finally, Amalgamated Bank raised its position in Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after buying an additional 2,459 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.